169 related articles for article (PubMed ID: 21156844)
1. Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations.
Jabbour E; Cortes J; Santos FP; Jones D; O'Brien S; Rondon G; Popat U; Giralt S; Kebriaei P; Jones RB; Kantarjian H; Champlin R; de Lima M
Blood; 2011 Mar; 117(13):3641-7. PubMed ID: 21156844
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms of Resistance to ABL Kinase Inhibition in Chronic Myeloid Leukemia and the Development of Next Generation ABL Kinase Inhibitors.
Patel AB; O'Hare T; Deininger MW
Hematol Oncol Clin North Am; 2017 Aug; 31(4):589-612. PubMed ID: 28673390
[TBL] [Abstract][Full Text] [Related]
3. Mutation analysis of BCR-ABL1 kinase domain in chronic myeloid leukemia patients with tyrosine kinase inhibitors resistance: a Malaysian cohort study.
Seman ZA; Ahid F; Kamaluddin NR; Sahid ENM; Esa E; Said SSM; Azman N; Mat WKDW; Abdullah J; Ali NA; Khalid MKNM; Yusoff YM
BMC Res Notes; 2024 Apr; 17(1):111. PubMed ID: 38643202
[TBL] [Abstract][Full Text] [Related]
4. Resistance to imatinib in patients with chronic myelogenous leukemia and the splice variant BCR-ABL1(35INS).
Berman E; Jhanwar S; Hedvat C; Arcila ME; Wahab OA; Levine R; Maloy M; Ma W; Albitar M
Leuk Res; 2016 Oct; 49():108-12. PubMed ID: 27658269
[TBL] [Abstract][Full Text] [Related]
5. Response and Resistance to BCR-ABL1-Targeted Therapies.
Braun TP; Eide CA; Druker BJ
Cancer Cell; 2020 Apr; 37(4):530-542. PubMed ID: 32289275
[TBL] [Abstract][Full Text] [Related]
6. An Update on the Management of Advanced Phase Chronic Myeloid Leukemia.
Short NJ; Senapati J; Jabbour E
Curr Hematol Malig Rep; 2023 Dec; 18(6):234-242. PubMed ID: 37651057
[TBL] [Abstract][Full Text] [Related]
7. Targeting FLT3-TAZ signaling to suppress drug resistance in blast phase chronic myeloid leukemia.
Shin JE; Kim SH; Kong M; Kim HR; Yoon S; Kee KM; Kim JA; Kim DH; Park SY; Park JH; Kim H; No KT; Lee HW; Gee HY; Hong S; Guan KL; Roe JS; Lee H; Kim DW; Park HW
Mol Cancer; 2023 Nov; 22(1):177. PubMed ID: 37932786
[TBL] [Abstract][Full Text] [Related]
8. Clinical Insights into Structure, Regulation, and Targeting of ABL Kinases in Human Leukemia.
Wu A; Liu X; Fruhstorfer C; Jiang X
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542279
[TBL] [Abstract][Full Text] [Related]
9. Chronic myeloid leukemia cells refractory/resistant to tyrosine kinase inhibitors are genetically unstable and may cause relapse and malignant progression to the terminal disease state.
Skorski T
Leuk Lymphoma; 2011 Feb; 52 Suppl 1(0 1):23-9. PubMed ID: 21299457
[TBL] [Abstract][Full Text] [Related]
10. The Impact of Pretransplant Use of Tyrosine Kinase Inhibitors on Allogeneic Stem Cell Transplantation in Patients with Chronic Myeloid Leukemia - A Single-institution Retrospective Study.
Fujita S; Kasahara H; Kato J; Koda Y; Shiroshita K; Yamaguchi K; Okayama M; Abe R; Kikuchi T; Shimizu T; Mori T; Kataoka K; Okamoto S
Intern Med; 2024 Jun; 63(11):1549-1562. PubMed ID: 37899244
[TBL] [Abstract][Full Text] [Related]
11. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results.
Hughes T; Deininger M; Hochhaus A; Branford S; Radich J; Kaeda J; Baccarani M; Cortes J; Cross NC; Druker BJ; Gabert J; Grimwade D; Hehlmann R; Kamel-Reid S; Lipton JH; Longtine J; Martinelli G; Saglio G; Soverini S; Stock W; Goldman JM
Blood; 2006 Jul; 108(1):28-37. PubMed ID: 16522812
[TBL] [Abstract][Full Text] [Related]
12. BCR::ABL1 kinase domain mutation testing and clinical outcome in a nationwide chronic myeloid leukemia patient population.
Kockerols C; Valk PJM; Blijlevens NMA; Cornelissen JJ; Dinmohamed AG; Geelen I; Hoogendoorn M; Janssen JJWM; Daenen LGM; Reijden BAV; Westerweel PE
Eur J Haematol; 2023 Dec; 111(6):938-945. PubMed ID: 37731314
[TBL] [Abstract][Full Text] [Related]
13. Chronic myeloid leukemia: advances in understanding disease biology and mechanisms of resistance to tyrosine kinase inhibitors.
Eide CA; O'Hare T
Curr Hematol Malig Rep; 2015 Jun; 10(2):158-66. PubMed ID: 25700679
[TBL] [Abstract][Full Text] [Related]
14. Beyond BCR::ABL1-The Role of Genomic Analyses in the Management of CML.
Branford S; Fernandes A; Shahrin N; Maqsood M; Shanmuganathan N; Wadham C
J Natl Compr Canc Netw; 2024 Feb; 22(1):. PubMed ID: 38394774
[TBL] [Abstract][Full Text] [Related]
15. Late relapse of chronic myeloid leukemia after allogeneic bone marrow transplantation points to KANSARL (KANSL1::ARL17A) alteration: a case report with insights on the molecular landscape.
Fontana D; Zambrotta GPM; Scannella A; Piazza R; Gambacorti-Passerini C
Ann Hematol; 2024 May; 103(5):1561-1568. PubMed ID: 38321229
[TBL] [Abstract][Full Text] [Related]
16. Next-generation sequencing for BCR-ABL1 kinase domain mutation testing in patients with chronic myeloid leukemia: a position paper.
Soverini S; Abruzzese E; Bocchia M; Bonifacio M; Galimberti S; Gozzini A; Iurlo A; Luciano L; Pregno P; Rosti G; Saglio G; Stagno F; Tiribelli M; Vigneri P; Barosi G; Breccia M
J Hematol Oncol; 2019 Dec; 12(1):131. PubMed ID: 31801582
[TBL] [Abstract][Full Text] [Related]
17. Predictive nonlinear modeling of malignant myelopoiesis and tyrosine kinase inhibitor therapy.
Rodriguez J; Iniguez A; Jena N; Tata P; Liu ZY; Lander AD; Lowengrub J; Van Etten RA
Elife; 2023 Apr; 12():. PubMed ID: 37115622
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic Choices in Patients with Ph-Positive Chronic Myelogenous Leukemia In Mexico in the Era of Tyrosine Kinase Inhibitors: Stem Cell Transplantation or Tyrosine Kinase Inhibitors? Fifteen Years Later.
Max RN; Daniela SB; Moisés M GP; Edgar J HF; Merittzel A MR; María de L PM; Juan C OG; Guillermo J RD; Guillermo J RA
Rev Invest Clin; 2024; 76(2):91-96. PubMed ID: 38740380
[TBL] [Abstract][Full Text] [Related]
19. Expert opinion-management of chronic myeloid leukemia after resistance to second-generation tyrosine kinase inhibitors.
Hochhaus A; Breccia M; Saglio G; García-Gutiérrez V; Réa D; Janssen J; Apperley J
Leukemia; 2020 Jun; 34(6):1495-1502. PubMed ID: 32366938
[TBL] [Abstract][Full Text] [Related]
20. Stem cell allografting for chronic Myeloid leukemia in the tyrosine kinase era - forgotten but not gone.
Tang K; Lipton JH
Leuk Lymphoma; 2024 Jun; 65(6):705-714. PubMed ID: 38335007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
